门冬氨酸鸟氨酸联合精氨酸治疗肝硬化肝性脑病的临床研究

目的观察门冬氨酸鸟氨酸(瑞甘)联合精氨酸治疗肝硬化并发肝性脑病的临床疗效。方法将84例肝硬化并发肝性脑病的患者随机分为治疗组和对照组。治疗组采用精氨酸加门冬氨酸鸟氨酸(瑞甘),对照组仅用精氨酸治疗,药物均用7d,两组其他基础治疗相同,治疗前后测定血氨含量、TBIL,并观察肝性脑病转归的影响、临床有效率。结果门冬氨酸鸟氨酸(瑞甘)联合精氨酸治疗肝硬化并发肝性脑病对降低血氨、TBIL和肝性脑病评分改善等明显优于单用精氨酸(P<0.05),临床显效率及总有效率高于对照组,两组间差异有统计学意义(P<0.05)。结论门冬氨酸鸟氨酸(瑞甘)联合精氨酸治疗肝硬化并发肝性脑病疗效确切,效果优于单用精氨酸,且无不良反应发生率增加,有较好临床推广价值。

Clinical efficacy of Rigan and Arginine in the treatment of hepatic encephalopathy caused by cirrhosis of liver

Objective To observe the effect of L-ornithine-L-aspartate and Rigan in the treatment of liver cirrhosis complicated with hepatic encephalopathy.Methods Eighty-four cases patients of liver cirrhosis complicated with hepatic encephalopathy were divided into two groups,forty-eight cases in observation group were given Rigan and Arginine,and forty cases in control group were only given Arginine.Two groups of patients were given the same primary treating,based on these treatment,observation group plus Rigan and Arginine,control group plus Arginine for 7 days.The blood ammonia,TBIL and the state of mind were examined before and after treatment.Results L-ornithine-L-aspartate and Rigan reduced the blood ammonia,TBIL and improved the state of mind,it surpassed the arginine obviously（P0.05）.Conclusions Rigan and Arginine has definite effect in the treatment of hepatic encephalopathy caused by cirrhosis of liver,its incidence of side effect is low,it has the value for clinical use.